Project Grant RF1AG096648
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institute on Aging awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $357,000 under the Aging Research program (CFDA 93.866) on September 1, 2026, to investigate endothelial pannexin1-induced inflammation in Alzheimer's disease. The research tests the hypothesis that amyloid-beta upregulates cerebral endothelial pannexin1 expression, which promotes vascular dysfunction and Alzheimer's disease progression through increased neuroinflammation and...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $518,555 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop spatially validated human lymphoid follicles-on-chip for modeling inflammaging and age-related immune dysfunction. The recipient will establish a lymphoid follicle organ-on-chip platform that recapitulates key hallmarks of human lymphoid function, including germinal center formation, AID expression, and antiviral antibody...
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. $751,786 on July 15, 2026, under the Aging Research program (CFDA 93.866) to identify genetic and plasma biomarkers that predict individual response to anti-amyloid-beta monoclonal antibody therapies for Alzheimer's disease. The project will investigate whether plasma biomarkers and microglia/astrocyte-specific polygenic Alzheimer's disease risk variants can predict amyloid-beta clearance, amyloid-related imaging...
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. a cooperative agreement totaling $1,478,201 on August 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a two-phase clinical drug development program evaluating lamivudine (3TC), a reverse transcriptase inhibitor, as a potential treatment to prevent and slow Alzheimer's disease in people with Down syndrome. The research addresses evidence that aberrant activation of retrotransposons—transposable...
- The National Institute of Neurological Disorders and Stroke awarded the University of Arizona $102,368 on June 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to characterize the brain's lymphatic drainage in an Alzheimer's disease rat model and investigate two therapies—manual lymphatic drainage and lymphaticovenous anastomosis—for repurposing to Alzheimer's disease treatment. The research addresses an unmet need in...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $761,496 on June 15, 2026, to investigate epigenetic mechanisms linking delirium and cognitive decline under the Aging Research program (CFDA 93.866). The recipient will test the hypothesis that epigenetic risk, measured by DNA methylation, identifies individuals with a vulnerable brain predisposed to delirium, cognitive decline, and Alzheimer's disease and Alzheimer's disease-related dementias in the setting of...
- The National Institute of Child Health and Human Development awarded Beth Israel Deaconess Medical Center $724,852 on September 1, 2026, under CFDA 93.865 (Child Health and Human Development Extramural Research) to investigate lymphatic pathology caused by dysregulated NFATC1 signaling using Down syndrome as a model. The research will examine how increased dosage of chromosome 21 genes DYRK1A and DSCR1 drives NFATC1 hyperphosphorylation and functional suppression, disrupting lymphatic...
- The National Institute on Aging awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,139,309 for a Project Grant (R01AG094755) on April 15, 2026, under the Aging Research program (CFDA 93.866). The recipient will develop advanced high-resolution MRI methods to noninvasively track cerebrospinal fluid flow and soluble amyloid-beta diffusion through perivascular spaces in the brain. The project tests three specific aims: developing and optimizing novel MR...
- The National Institute on Aging awarded Brigham & Women's Hospital $889,734 on September 1, 2026, under the Aging Research program (CFDA 93.866) to advance care planning for older individuals with Down syndrome experiencing early-onset and accelerated dementia. The award funds a mechanistic evaluation of the Serious Illness Care Program (SICP)—a multi-modal intervention comprising a structured conversation guide and clinician training—tailored to older individuals with Down syndrome facing...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...